Experience with neoadjuvant chemotherapy in patients with breast cancer

Khawaja Farhan Zahid, Muhammad Kamran Siddique, Neelam Siddiqui, Narjis Muzaffar, Muhammad Asim, Muhammad Azfar

Research output: Contribution to journalArticle

Abstract

Objective: To determine the response rates to neoadjuvant chemotherapy in patients with breast cancer. Methods: Medical records of 161 women with breast cancer, registered at Shaukat Khanum Memorial Cancer Hospital between July 2006 and March 2008 were retrospectively reviewed. Patients were stratified into two groups based on the type of chemotherapy received; Group A (Anthracycline based regimens), Group B (Anthracycline and Taxane based regimens). Response rate was noted. Results: Clinical complete response rates by clinical examination were significantly higher in Group B as compared to Group A in both primary disease in breast and axillary nodes (39% vs. 20.3%, p = 0.01; 72.7% vs. 30.7%, p = 0.01, respectively). There was no difference in response rates by imaging between groups A and B in breast and axillary lymph nodes (12.5% vs. 17%, p = 0.4; 66.6% vs. 70.4%, p = 0.4, respectively). There was no difference in pCR rates between Group A and B (9.1% vs. 14.2%, p = 0.35). However, multivariate analysis showed significant increase in pCR rates by addition of taxanes (p = 0.028), in patients with poorly differentiated tumours (p = 0.028) and in those with axillary node negative disease by palpation (p = 0.016). There was no statistically significant difference in breast conservation rates between group A and B (25.4% vs. 36.7%, p = 0.1). Conclusion: Addition of taxanes to anthracycline based regimens improved the pathological complete response in our patients with breast cancer.

Original languageEnglish
Pages (from-to)284-287
Number of pages4
JournalJournal of the Pakistan Medical Association
Volume60
Issue number4
Publication statusPublished - Apr 2010

Fingerprint

Anthracyclines
Breast Neoplasms
Drug Therapy
Taxoids
Breast
Cancer Care Facilities
Breast Diseases
Palpation
Medical Records
Multivariate Analysis
Lymph Nodes
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Zahid, K. F., Siddique, M. K., Siddiqui, N., Muzaffar, N., Asim, M., & Azfar, M. (2010). Experience with neoadjuvant chemotherapy in patients with breast cancer. Journal of the Pakistan Medical Association, 60(4), 284-287.

Experience with neoadjuvant chemotherapy in patients with breast cancer. / Zahid, Khawaja Farhan; Siddique, Muhammad Kamran; Siddiqui, Neelam; Muzaffar, Narjis; Asim, Muhammad; Azfar, Muhammad.

In: Journal of the Pakistan Medical Association, Vol. 60, No. 4, 04.2010, p. 284-287.

Research output: Contribution to journalArticle

Zahid, KF, Siddique, MK, Siddiqui, N, Muzaffar, N, Asim, M & Azfar, M 2010, 'Experience with neoadjuvant chemotherapy in patients with breast cancer', Journal of the Pakistan Medical Association, vol. 60, no. 4, pp. 284-287.
Zahid, Khawaja Farhan ; Siddique, Muhammad Kamran ; Siddiqui, Neelam ; Muzaffar, Narjis ; Asim, Muhammad ; Azfar, Muhammad. / Experience with neoadjuvant chemotherapy in patients with breast cancer. In: Journal of the Pakistan Medical Association. 2010 ; Vol. 60, No. 4. pp. 284-287.
@article{4fcf8df1f52142c3b7d1019cbc02cb73,
title = "Experience with neoadjuvant chemotherapy in patients with breast cancer",
abstract = "Objective: To determine the response rates to neoadjuvant chemotherapy in patients with breast cancer. Methods: Medical records of 161 women with breast cancer, registered at Shaukat Khanum Memorial Cancer Hospital between July 2006 and March 2008 were retrospectively reviewed. Patients were stratified into two groups based on the type of chemotherapy received; Group A (Anthracycline based regimens), Group B (Anthracycline and Taxane based regimens). Response rate was noted. Results: Clinical complete response rates by clinical examination were significantly higher in Group B as compared to Group A in both primary disease in breast and axillary nodes (39{\%} vs. 20.3{\%}, p = 0.01; 72.7{\%} vs. 30.7{\%}, p = 0.01, respectively). There was no difference in response rates by imaging between groups A and B in breast and axillary lymph nodes (12.5{\%} vs. 17{\%}, p = 0.4; 66.6{\%} vs. 70.4{\%}, p = 0.4, respectively). There was no difference in pCR rates between Group A and B (9.1{\%} vs. 14.2{\%}, p = 0.35). However, multivariate analysis showed significant increase in pCR rates by addition of taxanes (p = 0.028), in patients with poorly differentiated tumours (p = 0.028) and in those with axillary node negative disease by palpation (p = 0.016). There was no statistically significant difference in breast conservation rates between group A and B (25.4{\%} vs. 36.7{\%}, p = 0.1). Conclusion: Addition of taxanes to anthracycline based regimens improved the pathological complete response in our patients with breast cancer.",
author = "Zahid, {Khawaja Farhan} and Siddique, {Muhammad Kamran} and Neelam Siddiqui and Narjis Muzaffar and Muhammad Asim and Muhammad Azfar",
year = "2010",
month = "4",
language = "English",
volume = "60",
pages = "284--287",
journal = "JPMA. The Journal of the Pakistan Medical Association",
issn = "0030-9982",
publisher = "Pakistan Medical Association",
number = "4",

}

TY - JOUR

T1 - Experience with neoadjuvant chemotherapy in patients with breast cancer

AU - Zahid, Khawaja Farhan

AU - Siddique, Muhammad Kamran

AU - Siddiqui, Neelam

AU - Muzaffar, Narjis

AU - Asim, Muhammad

AU - Azfar, Muhammad

PY - 2010/4

Y1 - 2010/4

N2 - Objective: To determine the response rates to neoadjuvant chemotherapy in patients with breast cancer. Methods: Medical records of 161 women with breast cancer, registered at Shaukat Khanum Memorial Cancer Hospital between July 2006 and March 2008 were retrospectively reviewed. Patients were stratified into two groups based on the type of chemotherapy received; Group A (Anthracycline based regimens), Group B (Anthracycline and Taxane based regimens). Response rate was noted. Results: Clinical complete response rates by clinical examination were significantly higher in Group B as compared to Group A in both primary disease in breast and axillary nodes (39% vs. 20.3%, p = 0.01; 72.7% vs. 30.7%, p = 0.01, respectively). There was no difference in response rates by imaging between groups A and B in breast and axillary lymph nodes (12.5% vs. 17%, p = 0.4; 66.6% vs. 70.4%, p = 0.4, respectively). There was no difference in pCR rates between Group A and B (9.1% vs. 14.2%, p = 0.35). However, multivariate analysis showed significant increase in pCR rates by addition of taxanes (p = 0.028), in patients with poorly differentiated tumours (p = 0.028) and in those with axillary node negative disease by palpation (p = 0.016). There was no statistically significant difference in breast conservation rates between group A and B (25.4% vs. 36.7%, p = 0.1). Conclusion: Addition of taxanes to anthracycline based regimens improved the pathological complete response in our patients with breast cancer.

AB - Objective: To determine the response rates to neoadjuvant chemotherapy in patients with breast cancer. Methods: Medical records of 161 women with breast cancer, registered at Shaukat Khanum Memorial Cancer Hospital between July 2006 and March 2008 were retrospectively reviewed. Patients were stratified into two groups based on the type of chemotherapy received; Group A (Anthracycline based regimens), Group B (Anthracycline and Taxane based regimens). Response rate was noted. Results: Clinical complete response rates by clinical examination were significantly higher in Group B as compared to Group A in both primary disease in breast and axillary nodes (39% vs. 20.3%, p = 0.01; 72.7% vs. 30.7%, p = 0.01, respectively). There was no difference in response rates by imaging between groups A and B in breast and axillary lymph nodes (12.5% vs. 17%, p = 0.4; 66.6% vs. 70.4%, p = 0.4, respectively). There was no difference in pCR rates between Group A and B (9.1% vs. 14.2%, p = 0.35). However, multivariate analysis showed significant increase in pCR rates by addition of taxanes (p = 0.028), in patients with poorly differentiated tumours (p = 0.028) and in those with axillary node negative disease by palpation (p = 0.016). There was no statistically significant difference in breast conservation rates between group A and B (25.4% vs. 36.7%, p = 0.1). Conclusion: Addition of taxanes to anthracycline based regimens improved the pathological complete response in our patients with breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=77950441085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950441085&partnerID=8YFLogxK

M3 - Article

C2 - 20419971

AN - SCOPUS:77950441085

VL - 60

SP - 284

EP - 287

JO - JPMA. The Journal of the Pakistan Medical Association

JF - JPMA. The Journal of the Pakistan Medical Association

SN - 0030-9982

IS - 4

ER -